Compare Quest Diagnostics Inc (DGX) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs S&P Global Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while S&P Global Inc trades at $407.82 (market cap $118.72B). The key difference: S&P Global Inc is far larger — about 4.7× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and S&P Global Inc for 123 Days on average.
| DGX | SPGI | |
|---|---|---|
Market Cap | $25.48B | $118.72B |
Volume | 941,866 | 1,647,917 |
Sector | Health | Financials |
52-Week High | $247.45 | $517.92 |
52-Week Low | $173.49 | $370.42 |
Typical Hold Time | 56 Days | 123 Days |
Enterprise Value | $31.23B | $130.21B |
Dividend Yield | 1.49% | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
S&P Global (SPGI) trades at $402.73, up 1.91% with strong analyst support (85.7% buy ratings) and a $509.50 consensus price target. The stock shows solid fundamentals with 30.54% net margins and consistent revenue growth from $14.2B to $15.3B. Recent technical indicators show bearish momentum despite beating earnings expectations in two of the last three quarters. The company continues expanding through strategic acquisitions like OpenZeppelin and new product launches in digital asset risk assessment.
SPGI presents a compelling growth story with expanding margins and strategic positioning in financial data services. Key risks include market sensitivity to economic cycles and integration challenges from recent acquisitions. With strong cash flow generation and a dominant market position, the stock offers upside potential despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
